Delivery Order SPE2DB22D2206-SPE2DB25FKD66
- Not listed
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $39,778.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Scemblix 40 mg tablets (60-count units). The contract, which is not set-aside and was competitively awarded, is scheduled for completion by October 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product, with completion scheduled for July 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $13,259.50 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product for federal medical supply needs. The contract was competitively awarded without a set-aside designation and is scheduled for completion by October 14, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through the...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 units of Scemblix 40 mg tablets, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency has awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units), with a completion deadline of September 26, 2025. This competitive, non-set-aside contract reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract will be performed at the contractor's corporate office...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $26,519.00 for 60 tablets of Scemblix 40 mg by the Defense Logistics Agency's Medical Supply Chain on August 6, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The ultimate completion date is set for August 27, 2025, with performance to occur...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Scemblix 40 mg tablets (60-unit bottles) with a ceiling value of $13,259.50. This firm fixed-price delivery order is scheduled for completion by October 15, 2025, and represents fulfillment under a larger contract vehicle. The award was not designated as a set-aside and was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- The Defense Logistics Agency awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for supply of Scemblix 40 mg tablets (60 count) on September 5, 2025, with completion targeted for September 26, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKD66Delivery Order
The Defense Logistics Agency awarded a $80.8K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Scemblix 40 mg tablets (60-unit packages). The contract is classified as non-set-aside and represents a competitive award. Performance will be executed from the awardee's Conshohocken, Pennsylvania location, with an ultimate completion date of October 20, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that provides comprehensive global pharmaceutical support to military healthcare programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor. The company maintains an extensive portfolio of delivery orders through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military and veteran healthcare systems. The company's consistent competitive awards and substantial IDC position demonstrate its established capability to meet rigorous federal pharmaceutical procurement requirements and support Defense Health Agency operations and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $80.8k | 9/28/25 |